ValuEngine upgraded shares of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) from a sell rating to a hold rating in a report published on Tuesday.

Several other analysts have also recently issued reports on the stock. Maxim Group set a $9.00 price objective on shares of Keryx Biopharmaceuticals and gave the company a buy rating in a research note on Thursday, July 27th. Morgan Stanley reaffirmed an equal weight rating and set a $7.00 price objective (up previously from $4.00) on shares of Keryx Biopharmaceuticals in a research note on Tuesday, July 25th. BidaskClub cut shares of Keryx Biopharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, July 25th. Cowen and Company reaffirmed a market perform rating on shares of Keryx Biopharmaceuticals in a research note on Tuesday, July 25th. Finally, Zacks Investment Research cut shares of Keryx Biopharmaceuticals from a buy rating to a hold rating in a research note on Monday, July 17th. Seven investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company currently has an average rating of Hold and a consensus target price of $7.48.

Shares of Keryx Biopharmaceuticals (NASDAQ KERX) traded down 0.43% on Tuesday, hitting $6.97. 1,224,936 shares of the company were exchanged. Keryx Biopharmaceuticals has a 52-week low of $4.03 and a 52-week high of $8.38. The stock’s market capitalization is $827.69 million. The firm’s 50-day moving average is $7.14 and its 200-day moving average is $6.10.

Keryx Biopharmaceuticals (NASDAQ:KERX) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.60. Keryx Biopharmaceuticals had a negative net margin of 431.89% and a negative return on equity of 2,902.87%. The business had revenue of $15.10 million for the quarter, compared to analysts’ expectations of $14.51 million. During the same period in the prior year, the company posted ($0.42) EPS. The firm’s revenue was up 62.4% on a year-over-year basis. Equities research analysts predict that Keryx Biopharmaceuticals will post ($1.07) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “ValuEngine Upgrades Keryx Biopharmaceuticals, Inc. (KERX) to “Hold”” was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.dailypolitical.com/2017/08/04/valuengine-upgrades-keryx-biopharmaceuticals-inc-kerx-to-hold.html.

Several hedge funds have recently bought and sold shares of the stock. Stifel Financial Corp boosted its stake in Keryx Biopharmaceuticals by 11.5% in the first quarter. Stifel Financial Corp now owns 33,736 shares of the biopharmaceutical company’s stock valued at $207,000 after buying an additional 3,478 shares during the period. Rice Hall James & Associates LLC boosted its stake in Keryx Biopharmaceuticals by 3.0% in the first quarter. Rice Hall James & Associates LLC now owns 1,340,649 shares of the biopharmaceutical company’s stock valued at $8,258,000 after buying an additional 39,656 shares during the period. Janney Montgomery Scott LLC boosted its stake in Keryx Biopharmaceuticals by 29.1% in the first quarter. Janney Montgomery Scott LLC now owns 66,565 shares of the biopharmaceutical company’s stock valued at $410,000 after buying an additional 15,000 shares during the period. Bank of Montreal Can purchased a new stake in Keryx Biopharmaceuticals during the first quarter valued at $434,000. Finally, Metropolitan Life Insurance Co. NY boosted its stake in Keryx Biopharmaceuticals by 6.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 64,077 shares of the biopharmaceutical company’s stock valued at $375,000 after buying an additional 3,994 shares during the period. 62.35% of the stock is owned by institutional investors and hedge funds.

About Keryx Biopharmaceuticals

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.